Introduction {#s1}
============

The prevalence of atopy and asthma has increased worldwide [@pone.0004060-Anderson1]. The "hygiene hypothesis," that reduced childhood exposure to microorganisms modifies polarized Th1/Th2 responses leading to more allergic disorders, has been proposed to explain this increase [@pone.0004060-Strachan1]. Relevant microbial exposures may include gastrointestinal biota. Intestinal microbiota differ between healthy infants in countries with low or high allergy prevalence, as well as between allergic and non-allergic infants [@pone.0004060-Sepp1]. Early exposure to orofecal microbes such as Hepatitis A, appears to protect against allergen sensitization [@pone.0004060-Bjorksten1]--[@pone.0004060-Matricardi2], and in Italian military recruits and Danish adults, HAV, *Toxoplasma gondii*, and *Helicobacter pylori*, are inversely associated with atopy [@pone.0004060-Matricardi3], [@pone.0004060-Linneberg1].

*H. pylori*, gram-negative, microaerophilic gastric bacteria persistently colonize much of the world\'s population. Whereas nearly all adults are *H. pylori*-positive in developing countries, with socioeconomic development, prevalence has decreased substantially [@pone.0004060-Dooley1], [@pone.0004060-Kosunen1]. *H. pylori* is almost exclusively acquired in childhood [@pone.0004060-Blaser1], [@pone.0004060-Rowland1] and antibody responses are present for decades or for life, consistent with the persistent gastric colonization [@pone.0004060-Dooley1], [@pone.0004060-Kosunen1], [@pone.0004060-PerezPerez1]. *H. pylori* virulence is affected by the presence of the 35-40-kb *cag* pathogenicity island that can be detected by identification of the *cagA* gene or its product (CagA) [@pone.0004060-Blaser2]. CagA*+* strains are more host-interactive [@pone.0004060-Blaser2], [@pone.0004060-Odenbreit1]. *H. pylori* colonization induces continuous gastric inflammation, which is more pronounced with *cagA+* strains [@pone.0004060-Suerbaum1], and leads toward diminished gastric acidity [@pone.0004060-Kuipers1]. Serologic assays to detect antibodies to the CagA protein enhance overall detection of *H. pylori*, and specifically detection of the more interactive (CagA+) organisms [@pone.0004060-Everhart1]. Antibodies to CagA persist for at least two decades in the absence of antimicrobial treatments that eliminate *H. pylori* [@pone.0004060-PerezPerez1].

We hypothesized that the presence of *H. pylori* antibodies would be inversely related to asthma and that *cagA+* strains of *H. pylori* would have a more pronounced inverse relationship with asthma. A recent cross-sectional study of adults in Iceland, Estonia and Sweden suggested an inverse association of antibodies to *H. pylori* and self-reported hay fever or asthma [@pone.0004060-Thjodleifsson1]. In the NHANES III population, we demonstrated an inverse association of ever having had asthma with a *cagA*+ *H. pylori* strain [@pone.0004060-Chen1] and in the NHANES IV population, in which CagA testing was not done, we found inverse associations of *H. pylori* status with childhood-onset asthma and allergic disorders [@pone.0004060-Chen2]. We now provide evidence showing an inverse association of CagA serology with asthma in a case control study of an additional well-characterized and separate adult urban population.

Methods {#s2}
=======

Study population {#s2a}
----------------

Asthma cases and non-asthma controls were recruited to participate in the New York University (NYU)/Bellevue Asthma Registry in New York City. The registry was approved by the Institutional Review Board of the New York University School of Medicine. All cases and controls signed informed consent. Letters informing patients of positive *H. pylori* serology were sent under an IRB-approved protocol. Cases were referred to the registry by the Bellevue Hospital Center Asthma Clinic and local clinics. Controls were referred by asthma cases and by enlisting individuals directly from the community and from other programs within Bellevue Hospital Center. A number of referrals from the cases were unintentionally genetically related and these individuals were accounted for in the statistical methods. Cases and controls were excluded if they were \<18 or ≥65 years old; were current smokers; had a history of \>10 pack-year tobacco use; or had an unstable cardiac disease, uncontrolled hypertension, lung disease other than asthma, or neuromuscular disease.

Questionnaires and evaluations were completed for 573 persons. Subjects were considered to have a diagnosis of "asthma" based on their response to questions derived from validated questionnaires [@pone.0004060-Burney1], [@pone.0004060-Asher1] used for international studies of asthma. All patients were seen by a physician or nurse with extensive experience in asthma diagnoses and management. Because most of these adult patients were using chronic medication for asthma or had longstanding disease, a 12% change in FEV~1~ was not used as a criterion for diagnosis. We confirmed our diagnosis with the published algorithm of Enright et al. [@pone.0004060-Enright1]. Twelve persons who could not be classified as either having asthma or being asthma-free and 35 individuals without serum samples were excluded from statistical analyses. Race and ethnicity were self-classified. The final study population included 526 subjects (318 asthma cases and 208 controls).

Serum antibody analysis {#s2b}
-----------------------

Serum anti-*H. pylori* IgG antibody levels were determined by ELISA using whole cell antigens [@pone.0004060-Everhart1]. CagA status was determined by a separate ELISA, based on the presence of serum IgG antibodies against orv220, a 65 kDa recombinant CagA truncated protein [@pone.0004060-Everhart1], [@pone.0004060-Blaser3]. Absence of *H. pylori* was defined as negativity in both the whole cell and CagA assays (*H. pylori* negative). Individuals were defined as colonized with *cagA* negativ*e H. pylori* strains if they had antibodies to the whole cell antigen but not to CagA (*H. pylori+*/CagA−). Subjects were defined as being colonized with *cagA+ H. pylori* strains if they were positive for CagA antibodies, whether or not they were positive for *H. pylori* antibodies (CagA*+*). Thirty one persons (5.9%) were CagA*+* but had *H. pylori* serological determinations that did not reach positive values, a finding consistent with previous studies in *H. pylori* culture-positive subjects [@pone.0004060-RomeroGallo1].

Allergy testing {#s2c}
---------------

Measurements of total serum IgE (total IgE) and allergen-specific IgE for allergens considered significant for the Northeastern United States were performed in a commercial laboratory (Pharmacia ImmunoCAP assay; Quest Diagnostics; Teterboro, NJ). Allergen results were available for 525 of the 526 subjects. An allergen-specific IgE level \>0.35 kilo-international units (kIU)/L was considered positive.

Spirometry {#s2d}
----------

Pre- and post-bronchodilator spirometry was performed according to American Thoracic Society guidelines [@pone.0004060-ATS1]; normal values were obtained from Hankinson et al. [@pone.0004060-Hankinson1]. Values were obtained on 516 subjects, but were not available for 10 subjects.

Statistical Methods {#s2e}
-------------------

Non-parametric Wilcoxon and Kruskall-Wallis tests were used for crude comparisons of quantitative variables among groups, and the chi-squared test used for comparisons of categorical variables. In multivariable analyses, generalized estimating equations (GEE) were used to confirm the findings because of the presence of matched sets of individuals that occurred when asthma cases referred family members to the study. Data from genetically related cases and controls (n = 104) were entered as "repeated measures" in GEE logistic and linear regression analyses to account for the potentially correlated nature of observations among related individuals [@pone.0004060-Hanley1]. GEE was used with a logit link for logistic regression analyses of risk factors for asthma; risk factors for allergen-specific IgE, and separately, for seropositivity to either *cagA− or cagA*+ strains of *H. pylori*. In multivariable analyses, we first included all potential confounders in models and then dropped from the models those potential confounders that did not substantially affect the odds ratios of the variables of interest. GEE analyses were conducted using SAS 9.1 Proc GENMOD (SAS Institute Inc., Cary, NC, USA, 2002). Kaplan-Meier estimation and Cox proportional hazards regression were used to investigate correlates of age of diagnoses of asthma.

Results {#s3}
=======

Characteristics of the study groups {#s3a}
-----------------------------------

Characteristics of the asthma cases and non-asthma controls are shown in [Table 1](#pone-0004060-t001){ref-type="table"}. Cases and controls were similar in age and gender. Cases were more often Hispanic, and income levels were lower in the cases than in the controls. Hispanic ethnicity was not associated with asthma status, once income and race were adjusted for via logistic regression. As expected, total IgE was elevated in the cases compared to the controls, and there was a significant association of asthma with atopy, as defined by the presence of at least one allergen-specific IgE. Lung function parameters including post-bronchodilator forced expiratory volume in one second (FEV~1~), post-bronchodilator forced vital capacity (FVC), and the ratio of FEV~1~/FVC were reduced in the cases compared to controls. These characteristics are consistent with expectations for an asthma population compared to a control population.

10.1371/journal.pone.0004060.t001

###### Characteristics of the case control study population.

![](pone.0004060.t001){#pone-0004060-t001-1}

  Characteristic                                                      Asthma cases (N = 318)   Controls (N = 208)   Crude Odds ratio (95% CI)   Adjusted[\*](#nt102){ref-type="table-fn"} Odds ratio (95% CI)   *p*-value[†](#nt101){ref-type="table-fn"}
  ------------------------------------------------------------------ ------------------------ -------------------- --------------------------- --------------------------------------------------------------- -------------------------------------------
  **Age--year** (median, IQR)                                              34 (18--64)            38 (18--64)                                                                                                                      0.4
  **Sex - no. (%)**                                                                                                                                                                                            
  Male                                                                      95 (29.9)              69 (33.2)                   1.0                                                                             
  Female                                                                    223 (70.1)             139 (66.8)            1.17 (0.8--1.7)                               0.97 (0.7--1.4)                         
  **Race--no. (%)**                                                                                                                                                                                            
  White                                                                     239 (75.2)             123 (59.1)                  1.0                                           1.0                               
  Black                                                                     53 (16.7)              40 (19.2)            0.68 (0.42--1.1)                              0.70 (0.43--1.1)                         
  Asian and other                                                            26 (8.2)              45 (21.6)            0.29 (0.17--0.52)                             0.35 (0.20--0.61)                        
  **Hispanic ethnicity--no. (%)**                                                                                                                                                                              
  No                                                                        130 (40.9)             131 (63.0)                  1.0                                           1.0                               
  Yes                                                                       188 (59.1)             77 (37.0)             2.5 (1.7--3.6)                                1.4 (0.8--2.2)                          
  **Yearly income--no. (%)**                                                                                                                                                                                   
  \<15 K                                                                    132 (41.5)             40 (19.2)                   1.0                                           1.0                               
  15--49 K                                                                  82 (25.8)              64 (30.8)            0.39 (0.23--0.65)                             0.39 (0.24--0.63)                        
  50--99 K                                                                  43 (13.5)              56 (26.9)            0.23 (0.13--0.41)                             0.26 (0.15--0.45)                        
  ≥100 K                                                                     11 (3.5)               19 (9.1)            0.18 (0.07--0.43)                             0.20 (0.09--0.47)                        
  No response or refused                                                    50 (15.7)              29 (13.9)            0.52 (0.28--0.97)                             0.54 (0.30--0.98)                        
  **Atopic status** [a](#nt103){ref-type="table-fn"} **- no. (%)**                                                                                                                                             
  Non-atopic                                                                74 (23.3)              95 (45.9)                   1.0                                                                             
  Atopic                                                                    244 (76.7)             112 (54.1)            2.80 (1.9--4.2)                               3.4 (2.2--5.0)                          
  **Total IgE - U/ml** (median, IQR)                                      129 (40--386)           42 (15--140)                                                                                                  \<0.0001[†](#nt101){ref-type="table-fn"}
  **Spirometry - % predicted** (median, IQR)                                                                                                                                                                   
  Post bd FEV~1~                                                           86 (74--97)            92 (85--101)                                                                                                                  \<0.0001
  Post bd FVC                                                              88 (78--98)            91 (82--100)                                                                                                                   \<0.02
  Post bd FEV~1~/FVC                                                       81 (75--85)            85 (81--87)                                                                                                                   \<0.0001

*p*-values are from the Wilcoxon test and are provided for quantitative variables.

Adjusted for income (using 5 categories shown in table) and race via logistic regression.

Atopy defined as presence of any allergen-specific IgE at a level \>35 kIU/L.

*H. pylori* status and asthma {#s3b}
-----------------------------

[Table 2](#pone-0004060-t002){ref-type="table"} shows the crude and adjusted odds ratios (OR) for asthma and H. pylori serostatus. Although there was a suggestion of an association of asthma with CagA+ status, the crude OR for asthma associated with *H. pylori+/*CagA*−* or CagA+ status failed reach significance. In contrast, after adjustment for race and income, there was a significant inverse association of asthma and CagA+ status with an OR of 0.63 (95% CI = 0.41--0.98). We also examined the association of atopy and CagA+ status with asthma using GEE logistic regression analysis to adjust for age, race, Hispanic ethnicity, income, and the genetic relatedness among some of the subjects ([Table 3](#pone-0004060-t003){ref-type="table"}). As expected, atopy was associated with asthma. The significant inverse association of CagA*+* status with asthma was again demonstrated (OR = 0.57, 95% CI = 0.36--0.89). Analyses that treated all subjects as independent also yielded similar results (data not shown). We also repeated the analyses limiting subjects to those who were neither genetically related nor referred by one another (N = 402). Unconditional logistic regression in this group, adjusted for age, income, education, race/ethnicity, and atopy continued to yield an inverse association of asthma with CagA+ status (OR = 0.49, 95% CI = 0.28--0.85). The inverse OR associated with CagA+ status also was not substantially altered when atopy was excluded from the model. Inclusion of variables representing presence of allergen-specific IgE antibodies or of log~10~IgE in the multiple logistic regression model for asthma also had no major impact on our primary finding of an inverse association with CagA*+ H. pylori* strains.

10.1371/journal.pone.0004060.t002

###### Association between *H. pylori* serostatus and asthma in asthma cases (N = 318) and non-asthma controls (N = 208).

![](pone.0004060.t002){#pone-0004060-t002-2}

                                Asthma cases N (%)   Controls N (%)   Crude OR (95% CI)   Adjusted[\*](#nt104){ref-type="table-fn"} OR (95% CI)
  ---------------------------- -------------------- ---------------- ------------------- -------------------------------------------------------
  ***H. pylori*** **status**                                                             
  *H. pylori−/*CagA−                171 (53.8)         108 (51.9)            1.0                                   1.0
  *H. pylori+/*CagA−                68 (21.4)          35 (16.8)      1.23 (0.74--2.03)                     0.94 (0.57--1.57)
  CagA+                             79 (24.8)          65 (31.3)      0.77 (0.50--1.18)                     0.63 (0.41--0.98)

Adjusted for income (using 5 categories shown in [Table 1](#pone-0004060-t001){ref-type="table"}) and race (white, black, other) via logistic regression.

10.1371/journal.pone.0004060.t003

###### Association between *H. pylori* status or atopy and asthma using generalized estimating equation (GEE) multiple logistic regression analysis (N = 525).

![](pone.0004060.t003){#pone-0004060-t003-3}

  Risk factor                                    Value          OR[a](#nt105){ref-type="table-fn"}      95% CI      *p*-value
  --------------------------------------- -------------------- ------------------------------------ -------------- -----------
  *H. pylori* status                          *H. pylori*−                     1.0                        --       
                                           *H. pylori+/*CagA−                  0.74                  (0.41--1.3)      0.39
                                                CagA*+*                        0.57                  (0.36--0.89)     0.02
  Atopy[b](#nt106){ref-type="table-fn"}            No                          1.0                        --       
                                                  Yes                          3.39                  (2.20--5.20)   \<0.0001

Multivariate analysis performed using GEE and adjusted for age (in years), education (in years), income, race (white, black, other) and Hispanic ethnicity.

Atopy defined as any allergen-specific IgE.

*H. pylori* as an asthma modifier {#s3c}
---------------------------------

We examined the relationship between *H.pylori* serostatus and IgE. Log~10~IgE was not associated with either *H. pylori+*/CagA− status or CagA*+* status after adjustment for differences in race, Hispanic ethnicity, and age (GEE, data not shown). No relationship was identified between atopy, and either *H. pylori*+/CagA− status or CagA+ status. Among atopic subjects (N = 356), 19.7% were *H. pylori*+/CagA− and 27.3% were CagA+, whereas among non-atopic subjects (N = 169), 19.3% were *H. pylori*+/CagA− and 27.8% were CagA+ (*p* = 0.99). Atopy also was not associated with *H. pylori* status in a multivariable GEE logistic regression model that included adjustments for race, Hispanic ethnicity, education and income. Similarly, atopy was not associated with *H. pylori* status in the control population (*p* = 0.8).

In addition, we examined whether *H. pylori* serostatus was an asthma modifier using post-bronchodilator FEV~1~ and FEV~1~/FVC as surrogates of asthma severity. There was a significant difference in FEV~1~ among the individuals with asthma who were CagA*+* (N = 76, median % predicted = 82.0 (interquartile range, IQR = 71--92) compared to those who were *H. pylori* negative (N = 170, median % predicted = 90.0, IQR = 77--100) (*p* = 0.008), although FEV~1~/FVC was not different between the two groups (median = 80.0% predicted, IQR = 74.0--86.5 in CagA+ subjects and 82.0%, IQR = 76--85 in *H. pylori*− subjects) (*p* = 0.4).

We next asked whether *H. pylori* serostatus was associated with the age of onset of asthma. Age of onset of asthma was similar among the *H. pylori+*/CagA− individuals (N = 64, median age = 19, IQR = 6--30) and the CagA+ individuals (N = 71, median age = 21, IQR = 8--34), but was substantially lower among the *H. pylori negative* individuals (N = 159, median age = 11 y, IQR = 5--23) (*p* = 0.006). Similar differences in age were noted when we assessed age at onset of symptoms (data not shown). We performed Kaplan-Meier analysis of the probability of age-related survival until a doctor\'s diagnosis of asthma ([Figure 1](#pone-0004060-g001){ref-type="fig"}) assuming that acquisition of *H. pylori* occurred close to the time of birth, as suggested in the literature [@pone.0004060-Rowland1], [@pone.0004060-Suerbaum1], [@pone.0004060-Banatvala1], [@pone.0004060-Malaty1]. Cox regression analysis adjusted for age and income (adjustment for race/ethnicity did not affect the results of this analysis) suggested a reduced hazard ratio (HR) in CagA*+* individuals compared to *H. pylori−* individuals (HR = 0.74, 95% CI = 0.54--1.02) whereas the HR for *H. pylori+*/CagA− individuals compared to *H. pylori−* individuals was not substantially different from 1 (HR = 0.93, 95% CI = 0.67--1.29). We further modeled ages at doctor\'s diagnosis of asthma by GEE to take into account potentially correlated times of diagnosis among genetically related family members and to adjust for potential confounders. This analysis showed a significantly greater age at doctor\'s diagnosis of asthma among CagA+ subjects compared with *H. pylor*i-negative subjects (*p* = 0.02).

![Kaplan-Meier estimation of asthma-free survival among 294 adults with asthma according to *H. pylori* status (-- -- -- *H. pylori* negative (n = 159); \-\-\-- *H. pylori*+/CagA− (n = 64); CagA+ (n = 71).^a^\
^a^ (Data for age of asthma onset are not available for 24 of the 318 cases).](pone.0004060.g001){#pone-0004060-g001}

Discussion {#s4}
==========

Reduced exposure to orofecal organisms has been suggested as an explanation for the increasing prevalence of atopy and asthma, but studies of multiple organisms have had conflicting results [@pone.0004060-Ramsey1]. We studied a racially and ethnically diverse urban population in a case control study to examine the relationship between asthma and *H. pylori* serostatus. *H. pylori* seroprevalence was common in both cases and controls, in accordance with national estimates [@pone.0004060-Everhart2]. Our analysis identified a trend towards an inverse association between *H. pylori* and asthma that became significant when we examined individuals who carried cagA+ *H. pylori* strains. Our data provide evidence that in an urban population, asthma is inversely associated with serologic evidence of the presence of cagA+ H. *pylori* strains. We used several different analytical approaches, and analytical results were highly consistent. Our findings support and expand upon our recent cross-sectional study of separate populations of individuals with an asthma diagnosis in the NHANES III and NHANES IV populations [@pone.0004060-Chen1], [@pone.0004060-Chen2], and now include subjects with spirometry and serum IgE determinations. Our analysis of age of onset of disease in an adult population, in which we detect a delay on onset of asthma in CagA+ individuals, is consistent with the age relationships reported in the two NHANES populations.

We did not detect an effect of *H. pylori* serostatus on total IgE or the presence of atopy in our population. This finding suggests that the ability of *H. pylori* exposure to modify asthma may be mediated via mechanisms other than those associated with IgE levels. Interestingly, although we detected a delay in the onset of asthma associated with the presence of CagA+ serology, FEV~1~ was reduced in this group. The finding of reduced lung function in individuals with a later age of onset of asthma is consistent with those recently reported [@pone.0004060-Cassino1]--[@pone.0004060-Moore1].

Potential mechanisms by which *H. pylori* could alter asthma presentation include immune modifications or an effect on gastro-esophageal reflux disease (GERD). Although *H. pylori* colonization recruits neutrophils, T and B lymphocytes and macrophages to the stomach [@pone.0004060-Suerbaum1], *H. pylori* generally persists for the host\'s lifetime [@pone.0004060-Everhart3], reflecting immune evasion and modification of host inflammatory, innate, and adaptive immune responses [@pone.0004060-Dooley1], [@pone.0004060-Blaser1], [@pone.0004060-Mai1], [@pone.0004060-OKeeffe1]. *H. pylori* may alter the polarized Th1/Th2 T cell response through dendritic cell-mediated T-cell expression of IL-12, TNF-α, and IFN-γ [@pone.0004060-Guiney1]--[@pone.0004060-Hafsi1], and *cagA* translocation induces IL-12 production [@pone.0004060-Segal1]. *H. pylori* colonization induces regulatory T cells including CD4^+^ CD25^+^ T cells that express the forkhead box P3 transcription factor (Foxp3) [@pone.0004060-Lundgren1], [@pone.0004060-Beswick1] and also induces indoleamine 2,3-dioxygenase, mechanisms that suppress T cell function [@pone.0004060-Raitala1]. IL-10 expression is increased in the gastric mucosa of children carrying *H. pylori* [@pone.0004060-Oderda1]. Such immunosuppressive and immunomodulatory effects have the potential to alter the effector phase of asthma as recently shown in murine models of helminth infection [@pone.0004060-Wilson1]. *Helicobacter pylori* upregulate Toll-like receptor 4 (TLR4) [@pone.0004060-Ishihara1], and although results are complex, human and murine studies suggest that activation of TLR4 may be protective against allergic asthma [@pone.0004060-Garantziotis1].

Associations between GERD and asthma also are well-established [@pone.0004060-Harding1]--[@pone.0004060-Harding2]. Longitudinal studies show that asthma is a risk factor for development of GERD, and that GERD can trigger asthma [@pone.0004060-Harding1]--[@pone.0004060-Harding2]. *H. pylori*, especially *cagA+* strains, are inversely associated with GERD [@pone.0004060-Blaser1], [@pone.0004060-Peek1]. Although we did not specifically assess for GERD in this study, the possibility exists that the inverse association between *H. pylori* and asthma reflects protection from GERD.

An alternative explanation for our findings is that *H. pylori* seronegativity is a surrogate for other phenomena such as the presence or absence of other indigenous biota, or merely reflects cumulative early life exposure to antibiotics, identified as a risk factor for asthma. Although possible, the specificity of the relationship to *cagA+* strains argues against this point. There are some potential limitations to this study. Although we do not know the age at which *H. pylori* was acquired in the cases or controls, multiple studies have demonstrated that nearly all acquisition that occurs does so at an early age, usually before the age of five [@pone.0004060-Blaser1], [@pone.0004060-Rowland1]. *H. pylori* antibodies reflect the present carriage of *H. pylori*, and its prior elimination due to antibiotic exposure could lead to seronegativity. Thus, the current serostatus could under-estimate *H. pylori* acquisition, but not persistence, since with long-term carriage of *H. pylori*, antibody levels are stable [@pone.0004060-Blaser1], [@pone.0004060-Blaser2].

One potential confounding factor could be greater antibiotic use in asthma cases than in controls, which would bias toward consequent elimination of *H. pylori*. The association of the inverse association with childhood-onset but not later-age onset asthma in this study ([Figure 1](#pone-0004060-g001){ref-type="fig"}), and two other recent studies [@pone.0004060-Chen1], [@pone.0004060-Chen2] as well as the specificity of the effect with *cagA^+^* positivity argues against that point. However, prospective studies will be needed to clarify this question.

Because adults were studied, the association of *H. pylori* with delay in asthma onset may be confounded by recall bias or delay in doctor diagnosis. Although these issues suggest the need for future prospective studies, our findings support those of our recent cross-sectional studies of NHANES populations [@pone.0004060-Chen1], [@pone.0004060-Chen2].

In conclusion, our data suggest that *H. pylori*, and specifically, CagA positivity is inversely associated with asthma and with a delay in the onset of asthma. That the association was strongest with *cagA+ H. pylori* strains suggests that the more intensive host-interaction of these organisms may influence disease expression.

We thank Maria Thomas, Nicole Beattie and Wanda Hoerning for their help in conducting this study, Susan Lee for technical support, and Robert Norman for analytic suggestions.

**Competing Interests:**Martin J. Blaser, as co-discoverer of cagA at Vanderbilt University can receive royalties from the commercial exploitation of cagA. No diagnostic tests are currently licensed. Dr. Reibman has no conflicts of interest to disclose. Dr. Marmor has no conflicts of interest to disclose. Dr. Filner has no conflicts of interest to disclose. Dr. Fernandez-Beros has no conflicts of interest to disclose. Dr. Rogers has no conflicts of interest to disclose. Dr. Perez Perez has no conflicts of interest to disclose.

**Funding:**MO 1RR00096, ES 000260 (JR, MM), RO1 GM63270 (MB), Colton Family Foundation, The Diane Belfer Program in Human Microbial Ecology, Senior Scholar Award of the Ellison Medical Foundation (MB). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

[^1]: Conceived and designed the experiments: JR LR MJB. Performed the experiments: GPP. Analyzed the data: JR MM JF MEFB LR GPP MJB. Contributed reagents/materials/analysis tools: JR MM MEFB MJB. Wrote the paper: JR MM JF MJB.
